MA44518A - Procédés d'inhibition d'angiogenèse chez un sujet qui en a besoin - Google Patents

Procédés d'inhibition d'angiogenèse chez un sujet qui en a besoin

Info

Publication number
MA44518A
MA44518A MA044518A MA44518A MA44518A MA 44518 A MA44518 A MA 44518A MA 044518 A MA044518 A MA 044518A MA 44518 A MA44518 A MA 44518A MA 44518 A MA44518 A MA 44518A
Authority
MA
Morocco
Prior art keywords
subject
needs
angiogenesis inhibition
inhibition processes
processes
Prior art date
Application number
MA044518A
Other languages
English (en)
Inventor
Gregory A Demopulos
Thomas Dudler
Hans-Wilhelm Schwaeble
Larry Tjoelker
Original Assignee
Omeros Corp
Univ Leicester
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Omeros Corp, Univ Leicester filed Critical Omeros Corp
Publication of MA44518A publication Critical patent/MA44518A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MA044518A 2016-03-31 2017-03-31 Procédés d'inhibition d'angiogenèse chez un sujet qui en a besoin MA44518A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662315857P 2016-03-31 2016-03-31

Publications (1)

Publication Number Publication Date
MA44518A true MA44518A (fr) 2019-02-06

Family

ID=59959191

Family Applications (1)

Application Number Title Priority Date Filing Date
MA044518A MA44518A (fr) 2016-03-31 2017-03-31 Procédés d'inhibition d'angiogenèse chez un sujet qui en a besoin

Country Status (19)

Country Link
US (2) US10870708B2 (fr)
EP (1) EP3436072A4 (fr)
JP (3) JP6865767B2 (fr)
KR (3) KR20180128941A (fr)
CN (3) CN115137816A (fr)
AU (2) AU2017240129B2 (fr)
BR (1) BR112018069732A2 (fr)
CA (2) CA3096270A1 (fr)
CL (1) CL2018002708A1 (fr)
EA (2) EA202191185A1 (fr)
GE (1) GEP20237466B (fr)
IL (2) IL262021B2 (fr)
MA (1) MA44518A (fr)
MX (2) MX2018011648A (fr)
MY (1) MY195432A (fr)
NZ (1) NZ745531A (fr)
PH (1) PH12018502046A1 (fr)
SG (2) SG10202009886SA (fr)
WO (1) WO2017173290A1 (fr)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20170170B1 (ar) 2016-08-31 2022-09-15 Omeros Corp صيغ لجسم مضاد تثبيطية لـ masp-2 بتركيز عالي ولزوجة منخفضة وأطقم، وطرق
CN107661492A (zh) * 2017-08-31 2018-02-06 中山大学中山眼科中心 Vegf‑b的新用途
CN107537026A (zh) * 2017-08-31 2018-01-05 中山大学中山眼科中心 Vegf‑b的应用
US11584714B2 (en) 2018-05-29 2023-02-21 Omeros Corporation MASP-2 inhibitors and methods of use
US11957956B2 (en) 2019-05-10 2024-04-16 Rehab2Fit Technologies, Inc. System, method and apparatus for rehabilitation and exercise
US11904207B2 (en) 2019-05-10 2024-02-20 Rehab2Fit Technologies, Inc. Method and system for using artificial intelligence to present a user interface representing a user's progress in various domains
US11433276B2 (en) 2019-05-10 2022-09-06 Rehab2Fit Technologies, Inc. Method and system for using artificial intelligence to independently adjust resistance of pedals based on leg strength
US11957960B2 (en) 2019-05-10 2024-04-16 Rehab2Fit Technologies Inc. Method and system for using artificial intelligence to adjust pedal resistance
US11896540B2 (en) 2019-06-24 2024-02-13 Rehab2Fit Technologies, Inc. Method and system for implementing an exercise protocol for osteogenesis and/or muscular hypertrophy
US11071597B2 (en) 2019-10-03 2021-07-27 Rom Technologies, Inc. Telemedicine for orthopedic treatment
US11915816B2 (en) 2019-10-03 2024-02-27 Rom Technologies, Inc. Systems and methods of using artificial intelligence and machine learning in a telemedical environment to predict user disease states
US11955222B2 (en) 2019-10-03 2024-04-09 Rom Technologies, Inc. System and method for determining, based on advanced metrics of actual performance of an electromechanical machine, medical procedure eligibility in order to ascertain survivability rates and measures of quality-of-life criteria
US11887717B2 (en) 2019-10-03 2024-01-30 Rom Technologies, Inc. System and method for using AI, machine learning and telemedicine to perform pulmonary rehabilitation via an electromechanical machine
US11955221B2 (en) * 2019-10-03 2024-04-09 Rom Technologies, Inc. System and method for using AI/ML to generate treatment plans to stimulate preferred angiogenesis
US11955223B2 (en) 2019-10-03 2024-04-09 Rom Technologies, Inc. System and method for using artificial intelligence and machine learning to provide an enhanced user interface presenting data pertaining to cardiac health, bariatric health, pulmonary health, and/or cardio-oncologic health for the purpose of performing preventative actions
US11915815B2 (en) 2019-10-03 2024-02-27 Rom Technologies, Inc. System and method for using artificial intelligence and machine learning and generic risk factors to improve cardiovascular health such that the need for additional cardiac interventions is mitigated
US11955220B2 (en) 2019-10-03 2024-04-09 Rom Technologies, Inc. System and method for using AI/ML and telemedicine for invasive surgical treatment to determine a cardiac treatment plan that uses an electromechanical machine
US11075000B2 (en) 2019-10-03 2021-07-27 Rom Technologies, Inc. Method and system for using virtual avatars associated with medical professionals during exercise sessions
US11961603B2 (en) 2019-10-03 2024-04-16 Rom Technologies, Inc. System and method for using AI ML and telemedicine to perform bariatric rehabilitation via an electromechanical machine
US11101028B2 (en) 2019-10-03 2021-08-24 Rom Technologies, Inc. Method and system using artificial intelligence to monitor user characteristics during a telemedicine session
US11923065B2 (en) 2019-10-03 2024-03-05 Rom Technologies, Inc. Systems and methods for using artificial intelligence and machine learning to detect abnormal heart rhythms of a user performing a treatment plan with an electromechanical machine
US11069436B2 (en) 2019-10-03 2021-07-20 Rom Technologies, Inc. System and method for use of telemedicine-enabled rehabilitative hardware and for encouraging rehabilitative compliance through patient-based virtual shared sessions with patient-enabled mutual encouragement across simulated social networks
US11978559B2 (en) 2019-10-03 2024-05-07 Rom Technologies, Inc. Systems and methods for remotely-enabled identification of a user infection
WO2021113698A1 (fr) 2019-12-04 2021-06-10 Omeros Corporation Inhibiteurs de masp-2 et procédés d'utilisation
WO2021113682A1 (fr) 2019-12-04 2021-06-10 Omeros Corporation Inhibiteurs de masp-2 et procédés d'utilisation
CN115052862A (zh) 2019-12-04 2022-09-13 奥默罗斯公司 Masp-2抑制剂和使用方法
US20210179612A1 (en) 2019-12-04 2021-06-17 Omeros Corporation Masp-2 inhibitors and methods of use
KR20220031412A (ko) 2020-09-04 2022-03-11 주식회사 엘지에너지솔루션 배터리 관리 장치 및 방법

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4331647A (en) 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5453566A (en) 1986-03-28 1995-09-26 Calgene, Inc. Antisense regulation of gene expression in plant/cells
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4987071A (en) 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
JP3046318B2 (ja) 1987-12-15 2000-05-29 ジーン・シアーズ・ピーティーワイ・リミテッド リボザイム
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB8822492D0 (en) 1988-09-24 1988-10-26 Considine J Apparatus for removing tumours from hollow organs of body
US5211657A (en) 1988-11-07 1993-05-18 The United States Government As Represented By The Secretary Of The Department Of Health And Human Services Laminin a chain deduced amino acid sequence, expression vectors and active synthetic peptides
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5549910A (en) 1989-03-31 1996-08-27 The Regents Of The University Of California Preparation of liposome and lipid complex compositions
EP0438803B1 (fr) 1990-01-26 1997-03-12 Immunomedics, Inc. Vaccins contre le cancer et les maladies infectieuses
JP3218637B2 (ja) 1990-07-26 2001-10-15 大正製薬株式会社 安定なリポソーム水懸濁液
US5789573A (en) 1990-08-14 1998-08-04 Isis Pharmaceuticals, Inc. Antisense inhibition of ICAM-1, E-selectin, and CMV IE1/IE2
JP2958076B2 (ja) 1990-08-27 1999-10-06 株式会社ビタミン研究所 遺伝子導入用多重膜リポソーム及び遺伝子捕捉多重膜リポソーム製剤並びにその製法
IL108367A0 (en) 1993-01-27 1994-04-12 Hektoen Inst For Medical Resea Antisense polynzcleotide inhibition of human growth factor-sensitive cancer cells
US5629327A (en) * 1993-03-01 1997-05-13 Childrens Hospital Medical Center Corp. Methods and compositions for inhibition of angiogenesis
US5801154A (en) 1993-10-18 1998-09-01 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of multidrug resistance-associated protein
US5741516A (en) 1994-06-20 1998-04-21 Inex Pharmaceuticals Corporation Sphingosomes for enhanced drug delivery
US5795587A (en) 1995-01-23 1998-08-18 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
US5738868A (en) 1995-07-18 1998-04-14 Lipogenics Ltd. Liposome compositions and kits therefor
US5739119A (en) 1996-11-15 1998-04-14 Galli; Rachel L. Antisense oligonucleotides specific for the muscarinic type 2 acetylcholine receptor MRNA
US7083786B2 (en) 1997-04-03 2006-08-01 Jensenius Jens Chr MASP-2, a complement-fixing enzyme, and uses for it
US6649592B1 (en) 2000-01-14 2003-11-18 Science & Technology Corporation @ Unm Peptide inhibitors of LFA-1/ICAM-1 interaction
SG98393A1 (en) 2000-05-19 2003-09-19 Inst Materials Research & Eng Injectable drug delivery systems with cyclodextrin-polymer based hydrogels
JP4723244B2 (ja) 2002-07-19 2011-07-13 オメロス コーポレイション 生分解性トリブロックコポリマー、その合成方法、ならびにそれから作製されるヒドロゲルおよび生体材料
US9096676B2 (en) 2003-05-12 2015-08-04 Helion Biotech Aps Antibodies to MASP-2
US7919094B2 (en) * 2004-06-10 2011-04-05 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
US20130266559A1 (en) 2004-06-10 2013-10-10 University Of Leicester Methods for Treating Conditions Associated with MASP-2 Dependent Complement Activation
US8840893B2 (en) * 2004-06-10 2014-09-23 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
US8168584B2 (en) * 2005-10-08 2012-05-01 Potentia Pharmaceuticals, Inc. Methods of treating age-related macular degeneration by compstatin and analogs thereof
US11130801B2 (en) 2011-01-13 2021-09-28 Case Western Reserve University Method for inhibiting platelet derived growth factor signaling with C3aR or C5aR antibodies
NZ746139A (en) * 2011-04-08 2023-11-24 Omeros Corp Methods for treating conditions associated with masp-2 dependent complement activation
RS60541B1 (sr) * 2011-05-04 2020-08-31 Omeros Corp Kompozicije za inhibiciju masp-2 zavisne aktivacije komplementa
EP3524258A1 (fr) * 2011-06-22 2019-08-14 Apellis Pharmaceuticals, Inc. Méthodes de traitement de troubles chroniques au moyen d'inhibiteurs de complément
RS61755B1 (sr) 2012-06-18 2021-05-31 Omeros Corp Kompozicije i postupci za inhibiciju masp-1 i/ili masp-2 i/ili masp-3 za tretman različitih bolesti i poremećaja
KR20160062186A (ko) 2013-10-17 2016-06-01 오메로스 코포레이션 Masp-2 의존성 보체 활성화와 관련된 상태의 치료 방법
JP6369862B2 (ja) 2014-08-06 2018-08-08 原　英彰 眼内血管新生抑制剤及びその用途

Also Published As

Publication number Publication date
CN117582494A (zh) 2024-02-23
CN109152834A (zh) 2019-01-04
CA3018774A1 (fr) 2017-10-05
JP2019513715A (ja) 2019-05-30
US10870708B2 (en) 2020-12-22
MX2018011648A (es) 2019-01-30
BR112018069732A2 (pt) 2019-02-05
NZ745531A (en) 2020-09-25
MY195432A (en) 2023-01-20
PH12018502046A1 (en) 2019-07-08
AU2020201633B2 (en) 2022-03-31
IL262021A (en) 2018-10-31
IL262021B2 (en) 2024-01-01
KR20200113290A (ko) 2020-10-06
IL262021B1 (en) 2023-09-01
AU2020201633A1 (en) 2020-03-19
IL305200A (en) 2023-10-01
CL2018002708A1 (es) 2019-01-11
EP3436072A1 (fr) 2019-02-06
SG10202009886SA (en) 2020-11-27
US20170283508A1 (en) 2017-10-05
KR20230019991A (ko) 2023-02-09
EA201892218A1 (ru) 2019-03-29
AU2017240129A1 (en) 2018-09-06
US11981748B2 (en) 2024-05-14
MX2022012380A (es) 2022-10-31
WO2017173290A1 (fr) 2017-10-05
EA202191185A1 (ru) 2021-10-29
JP6865767B2 (ja) 2021-04-28
CN115137816A (zh) 2022-10-04
EP3436072A4 (fr) 2019-11-06
GEP20237466B (en) 2023-01-25
JP2022110159A (ja) 2022-07-28
KR20180128941A (ko) 2018-12-04
CA3096270A1 (fr) 2017-10-05
CA3018774C (fr) 2023-02-28
SG11201808242UA (en) 2018-10-30
US20210189009A1 (en) 2021-06-24
JP2020125332A (ja) 2020-08-20
AU2017240129B2 (en) 2020-04-02

Similar Documents

Publication Publication Date Title
MA44518A (fr) Procédés d'inhibition d'angiogenèse chez un sujet qui en a besoin
DK3263782T3 (da) Indløbselement
UA35584S (uk) Ювелірний виріб «оберіг»
IL249690A0 (en) The clean collar sticker
UA33118S (uk) Підвіска «коловрат із зіркою русі»
UA34469S (uk) Брошка «шаучам»
GB201620178D0 (en) Concept 36 A
GB201620146D0 (en) Concept 36 A
UA33828S (uk) Емблема «мегамастер»
UA34208S (uk) Пряжка «драккар»
GB201620150D0 (en) Concept 11
GB201620152D0 (en) Concept 38
GB201620156D0 (en) Concept 42
GB201620129D0 (en) Concept 53
GB201620142D0 (en) Concept 31
GB201620144D0 (en) Concept 33
GB201620131D0 (en) Concept 16
UA34203S (uk) Підвіска «зігфрід»
GB201616434D0 (en) Concept 133
GB201616142D0 (en) Concept 132
GB201614310D0 (en) Concept 126
GB201614311D0 (en) Concept 22
GB201614312D0 (en) Concept 125
GB201613858D0 (en) Concept 122
GB201613342D0 (en) Concept 116